After a slow start to the month, the IPO market revved back to life with 13 IPOs coming to market this past week. SPAC activity picked up, with seven blank check IPOs raising $940 million. New filers continued to flood the IPO pipeline, with fourteen IPOs and...read more
Regencell Bioscience Holdings, which is developing formulations of traditional Chinese medicine for ADHD and autism, raised $22 million by offering 2.3 million shares at $9.50, within the range of $8.50 to $10.50. At pricing, the Hong Kong, China-based company...read more
Regencell Bioscience Holdings, which is developing formulations of traditional Chinese medicine for ADHD and ASD, announced terms for its IPO on Friday. The Hong Kong, China-based company plans to raise $22 million by offering 2.3 million shares at a price...read more
Regencell Bioscience Holdings, which is developing formulations of traditional Chinese medicine for ADHD and ASD, filed on Monday with the SEC to raise up to $18 million in an initial public offering. Regencell is focused on the research, development, and...read more
US IPO Weekly Recap: The summer IPO market heats up in a 13 IPO week
After a slow start to the month, the IPO market revved back to life with 13 IPOs coming to market this past week. SPAC activity picked up, with seven blank check IPOs raising $940 million. New filers continued to flood the IPO pipeline, with fourteen IPOs and...read more
Regencell Bioscience prices US IPO at $9.50 midpoint, studying traditional Chinese medicine
Regencell Bioscience Holdings, which is developing formulations of traditional Chinese medicine for ADHD and autism, raised $22 million by offering 2.3 million shares at $9.50, within the range of $8.50 to $10.50. At pricing, the Hong Kong, China-based company...read more
Chinese drug developer Regencell Bioscience sets terms for $22 million US IPO
Regencell Bioscience Holdings, which is developing formulations of traditional Chinese medicine for ADHD and ASD, announced terms for its IPO on Friday. The Hong Kong, China-based company plans to raise $22 million by offering 2.3 million shares at a price...read more
Chinese drug developer Regencell Bioscience files for an $18 million US IPO
Regencell Bioscience Holdings, which is developing formulations of traditional Chinese medicine for ADHD and ASD, filed on Monday with the SEC to raise up to $18 million in an initial public offering. Regencell is focused on the research, development, and...read more